BioXcel Therapeutics Inc
Change company Symbol lookup
Select an option...
BTAI BioXcel Therapeutics Inc
T AT&T Inc
VZ Verizon Communications Inc
CSPI CSP Inc
BXMT Blackstone Mortgage Trust Inc
PSNL Personalis Inc
PS Pluralsight Inc
POR Portland General Electric Co
PHI PLDT Inc
PD PagerDuty Inc
Go

Health Care : Biotechnology |
Company profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Price
Delayed
$41.68
Day's Change
-0.37 (-0.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
42.71
Day's Low
40.73
Volume
(Average)

Today's volume of 155,892 shares is on pace to be in-line with BTAI's 10-day average volume of 503,959 shares.

155,892

Display:

Providers:

UpdateCancel
6 providers
September 09, 2020
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta...(Globe Newswire)

August 14, 2020
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application ("NDA") submission to U.S. Food and Drug Administration ("FDA") planned for Q1 2021 Initiating the third dose cohort, 90 mcg, of the...(Globe Newswire)

August 07, 2020
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a...(Globe Newswire)

August 06, 2020
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta...(Globe Newswire)

July 28, 2020
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering...(Globe Newswire)

July 27, 2020
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. In...(Globe Newswire)

July 20, 2020
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested Statistically significant improvements in PEC score observed as early as 20 minutes after...(Globe Newswire)

July 09, 2020
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation

BioXcel Therapeutics ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today...(Globe Newswire)

July 07, 2020
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that it has received a...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.